Iron and clinical outcomes in dialysis and non-dialysis-dependent chronic kidney disease patients.
Abnormal iron homeostasis plays an important role in the anemia of chronic kidney disease (CKD). Although iron overload was the main complication seen in the pre-erythropoiesis-stimulating agent era, relative iron deficiency is much more common today in patients with CKD. Maintaining certain "desirable" levels of commonly used markers of iron stores (such as transferrin saturation ratio and serum ferritin) have become the goal of iron management in clinical practice, yet it is unclear whether achievement and maintenance of these "desirable" levels translates into improved clinical outcomes. This review examines issues related to iron and long-term clinical outcomes from an epidemiologic perspective, with the goal to determine what an ideal therapeutic approach should be in clinical practice and what future research is required to clarify important practical questions. Particular attention is devoted to patients with non-dialysis-dependent CKD because the management of iron homeostasis in this group of patients poses additional intriguing questions.
Kovesdy
Csaba P
CP
Division of Nephrology, Salem Veterans Affairs Medical Center, Salem, VA 24153, USA. csaba.kovesdy@va.gov
D004920:Erythropoiesis / Q000502:physiology; D005293:Ferritins / Q000097:blood; D006397:Hematinics / Q000627:therapeutic use; D006801:Humans; D007501:Iron / Q000378:metabolism*; D007676:Kidney Failure, Chronic / Q000097:blood* / Q000401:mortality / Q000628:therapy; D011379:Prognosis; D006435:Renal Dialysis; D015996:Survival Rate / Q000639:trends; D014168:Transferrin / Q000378:metabolism; D014481:United States / Q000453:epidemiology
D006397:Hematinics; D014168:Transferrin; D005293:Ferritins; D007501:Iron